Friction over drug patents

Differences over intellectual property rights (IPRs) have emerged as a strong undercurrent in India’s economic relations with the U.S. The attempt by the influential pharmaceutical lobby to stymie India’s efforts to ensure the supply of medicines at affordable rates without violating existing treaty commitments, requires a principled response from New